UK Gastrointestinal Therapeutics Market Size & Outlook
UK gastrointestinal therapeutics market, 2018-2030 (US$M)
Related Markets
UK gastrointestinal therapeutics market highlights
- The UK gastrointestinal therapeutics market generated a revenue of USD 2,075.1 million in 2022 and is expected to reach USD 2,489.4 million by 2030.
- The UK market is expected to grow at a CAGR of 2.3% from 2023 to 2030.
- In terms of segment, branded was the largest revenue generating drug type in 2022.
- Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
Gastrointestinal therapeutics market data book summary
| Market revenue in 2022 | USD 2,075.1 million |
| Market revenue in 2030 | USD 2,489.4 million |
| Growth rate | 2.3% (CAGR from 2022 to 2030) |
| Largest segment | Branded |
| Fastest growing segment | Generics |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Branded, Generics |
| Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
Other key industry trends
- In terms of revenue, UK accounted for 5.5% of the global gastrointestinal therapeutics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany gastrointestinal therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Spain is the fastest growing regional market in Europe and is projected to reach USD 1,227.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gastrointestinal Therapeutics Market Scope
Gastrointestinal Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK gastrointestinal therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 68.97% in 2022. Horizon Databook has segmented the UK gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
The UK is anticipated to witness lucrative growth in the near future, owing to the rising prevalence of gastrointestinal diseases in the country, rising number of initiatives undertaken by the government, and major market players working on enhancing treatment options for gastrointestinal diseases.
According to a study published by Crohn’s and Colitis UK, over 115,000 individuals in UK were diagnosed with Crohn’s disease, and over 146,000 individuals were diagnosed with ulcerative colitis in 2018.
The same source indicates that over 300,000 individuals in the UK were affected by IBD in 2018. There have been various initiatives undertaken by the government to enhance research for various treatment options.
Reasons to subscribe to UK gastrointestinal therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK gastrointestinal therapeutics market databook
-
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into UK gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK gastrointestinal therapeutics market size, by drug type, 2018-2030 (US$M)
UK Gastrointestinal Therapeutics Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
